Skip to Content

Amitiza Approval History

FDA Approved: Yes (First approved January 31, 2006)
Brand name: Amitiza
Generic name: lubiprostone
Dosage form: Capsules
Company: Sucampo Pharmaceuticals, Inc.
Treatment for: Constipation, Chronic, Irritable Bowel Syndrome

Amitiza (lubiprostone) is a selective chloride channel activator for the treatment of chronic idiopathic constipation and opioid-induced constipation in adults, and irritable bowel syndrome with constipation in adult women.

Development History and FDA Approval Process for Amitiza

DateArticle
Apr 23, 2013Approval FDA Approves Amitiza for Opioid-Induced Constipation
Sep 17, 2007FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Jan 31, 2006Approval Amitiza - Sucampo Pharmaceuticals, Inc. - Treatment for Constipation
Apr  1, 2005Sucampo Submits New Drug Application for Lubiprostone, an Investigational Compound for the Treatment of Chronic Idiopathic Constipation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide